Acelrx Pharmaceuticals Inc. buy stratec
Summary
This prediction ended on 23.03.20 with a price of €15.24. Massive losses of -74.09% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Acelrx Pharmaceuticals Inc. | 4.645% | 4.645% | -16.046% | -95.474% |
iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
Comments by stratec for this prediction
In the thread Acelrx Pharmaceuticals Inc. diskutieren
ACRX PDUFA action date November 3, 2018, for sufentanil for the management of moderate-to-severe pain
News: ACRX announced that the FDA has accepted their resubmission for their sublingual tablet formulation of sufentanil for the management of moderate-to-severe pain in a closely supervised setting. In addition, the FDA has indicated that the response is sufficient to warrant a full review, and a PDUFA action date has been set for November 3, 2018.
Looking forward: ACRX estimates that the market potential for this drug is $1.1 billion, so needless to say this is an important application for them. Whether the company has sufficiently addressed the concerns laid out in the complete response letter from last year remains to be seen. However, one could think it stands to reason that if the FDA accepted the resubmission that there is a strong chance that the issues have indeed been overcome.
In the thread Trading Acelrx Pharmaceuticals Inc.